Clinical Trial Detail

NCT ID NCT02626507
Title Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Eastchester Center for Cancer Care
Indications

Her2-receptor negative breast cancer

Therapies

Palbociclib

Gedatolisib

Goserelin

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST